.png | image2 = Nimodipine.gif | width = 194 | CAS_number = 66085-59-4 | ATC_prefix = C08 | ATC_suffix = CA06 | ATC_supplemental = | PubChem = 4497 | DrugBank = APRD00612 | chemical_formula = C₂₁H₂₆N₂O₇ | molecular_weight = 418.44 g/mol | smiles = | melting_point = 7 | bioavailability = 100% (Intravenous) 13% (Oral) | protein_bound = 95% | metabolism = Hepatic | elimination_half-life = 8-9 hours | pregnancy_category = C: (USA) | legal_status = | routes_of_administration = Intravenous, Oral }}

Nimodipine (marketed by Bayer as Nimotop®) is a dihydropyridine calcium channel blocker originally developed for the treatment of high blood pressure. It is not frequently used for this indication, but has shown good results in preventing a major complication of subarachnoid hemorrhage (a form of cerebral hemorrhage) termed vasospasm; this is now the main use of nimodipine.

Dosage

---

The regular dosage is 60 mg tablets four times daily. If the patient is unable to take tablets orally, it is given via intravenous infusion at a rate of 0.5-1 mg/hour (lower dosage if the body weight is <70 kg or blood pressure is too low).

Usage

---

Because it has some selectivity for cerebral vasculature, nimodipine's main use is in the prevention of cerebral vasospasm and resultant ischemia, a complication of subarachnoid hemorrhage (a form of cerebral bleed). Its administration begins within 4 days of a subarachnoid hemorrhage and is continued for three weeks. If blood pressure drops by over 5%, dosage is adjusted. There is still controversy regarding the use of intravenous nimodipine on a routine basis (Allen et al 1983, Janjua & Mayer 2003).

A 2003 trial (Belfort et al) found nimodipine was inferior to magnesium sulfate in preventing seizures in women with severe preeclampsia.

Mode of action

---

Nimodipine binds specifically to L-type voltage-gated calcium channels. There are numerous theories about its mechanism in preventing vasospasm, but none are conclusive.

Contraindications & side-effects

---

Nimodipine is associated with low blood pressure, flushing and sweating, edema, nausea and other gastrointestinal problems. It is contraindicated in unstable angina or an episode of myocardial infarction more recent than one month.

References

---

• Allen GS, Ahn HS, Preziosi TJ, Battye R, Boone SC, Boone SC, Chou SN, Kelly DL, Weir BK, Crabbe RA, Lavik PJ, Rosenbloom SB, Dorsey FC, Ingram CR, Mellits DE, Bertsch LA, Boisvert DP, Hundley MB, Johnson RK, Strom JA, Transou CR. Cerebral arterial spasm--a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med 1983;308:619-24. PMID 6338383.
• Belfort MA, Anthony J, Saade GR, Allen JC Jr; Nimodipine Study Group. A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. N Engl J Med 2003;348:304-11. PMID 12540643.
• Janjua N, Mayer SA. Cerebral vasospasm after subarachnoid hemorrhage. Curr Opin Crit Care 2003;9:113-9. PMID 12657973.
• Rang HP, Dale MM, Ritter JM, Moore PK. (2003) Pharmacology 5th edition. London, Churchill Livingstone.

External links

---

• Nimotop (manufacturer's website)
• Nimodipine (patient information)

Calcium channel blockers

Nimodipine